$13.08 $0.18 (1.4%)

08:00 PM EDT on 07/02/20

Akebia Therapeutics (NASDAQ:AKBA)

CAPS Rating: 4 out of 5

Current Price $13.08 Mkt Cap $1.8B
Open $0.00 P/E Ratio 0.00
Prev. Close $13.08 Div. (Yield) $0.00 (0.0%)
Daily Range $0.00 - $0.00 Volume 1,275,772
52-Wk Range $2.99 - $13.68 Avg. Daily Vol. 1,848,605


How do you think NASDAQ:AKBA will perform against the market?

Add Stock to CAPS Watchlist

All Players

61 Outperform
2 Underperform

All-Star Players

20 Outperform
0 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:AKBA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.10)
Submitted December 23, 2016

I'm not the kind of narcissistic psychopath who enjoys leading a Twitter stock cult, but if I was my chosen stock would be Akebia. I closed my recent outperform rating at a big loss in order to write an updated pitch, but in real life zzporte… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!



Fools bullish on NASDAQ:AKBA are also bullish on:

Fools bearish on NASDAQ:AKBA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about AKBA.


Member Avatar Paco57 (61.14) Submitted: 2/20/2020 9:28:16 PM : Outperform Start Price: $10.27 NASDAQ:AKBA Score: +34.49



Member Avatar odocoileus (57.33) Submitted: 2/2/2020 5:59:16 PM : Outperform Start Price: $10.66 NASDAQ:AKBA Score: -15.86

What a frustrating stock. I got caught up in the story of vadadustat and jumped the gun again, thinking there would be a slow burn run up. Competitor FGEN has had a market cap roughly 4 times the size of AKBA, surely AKBA would close the gap. Since then I've seen it go up to $12 down to $3 and now in the $7's. The merger with Keryx seemed like a good idea, but kind of hammered the share price. But I think we will see the wisdom of this merger if vadadustat gets approved. PH III results are due mid-2020. FGEN has a jump on AKBA in this area with their anemia drug roxadustat. But if AKBA's results are as good or better than FGEN's, they may jump ahead by leveraging the Keryx marketing engine, which has been marketing Auryxia to patients with chronic kidney disease for years. With a $4b market there is plenty of room for both companies to thrive.


Member Avatar MujamMojam (< 20) Submitted: 1/15/2020 11:38:11 PM : Outperform Start Price: $6.94 NASDAQ:AKBA Score: +93.88

I five years will be 100 stock. One of the most common complications of Chronic Kidney Disease (CKD) is chronic Anemia. Since Erythropoietin is produced in the kidneys. Current treatment (Epogen) has a lot of drawbacks. An oral alternative will be a God-send. The market is huge. Already this new drug has been proven to acheive the required hemoglobin level within 24 weeks of once day pill. Most likely we have a WINNER. May 2020 is the end of Phase III trial. I think AKBA is not looking back from this point onward.


Find the members with the highest scoring picks in AKBA.

Score Leader


Under5 (45.69) Score: +221.01

The Score Leader is the player with the highest score across all their picks in AKBA.

Member Name Member
Call Time
Score Commentary
NextGenStock 38.00 8/7/2019 Outperform 5Y $3.61 +262.33% +8.69% +253.63 0 Comment
Under5 45.69 11/6/2019 Outperform 5Y $3.85 +239.74% +1.56% +238.18 0 Comment
gunda7907 < 20 5/28/2019 Outperform 5Y $5.28 +147.73% +10.05% +137.68 0 Comment
conliskjr < 20 12/31/2018 Outperform 3Y $5.37 +143.58% +24.94% +118.63 0 Comment
pataylo 50.93 4/23/2019 Outperform 5Y $6.44 +103.11% +7.02% +96.09 1 Comment
MujamMojam < 20 1/16/2020 Outperform 5Y $6.94 +88.47% -5.40% +93.88 1 Comment
PHIL1120 75.64 1/11/2019 Outperform 1Y $6.24 +109.62% +21.01% +88.61 0 Comment
farhangp 55.79 3/20/2020 Outperform 5Y $5.95 +119.83% +31.45% +88.38 0 Comment
suspiciousmole < 20 4/8/2019 Outperform 5Y $7.00 +86.86% +8.23% +78.63 1 Comment
dpid 88.37 1/28/2020 Outperform 1Y $7.87 +66.31% -4.76% +71.06 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AKBA.